IBRX

ImmunityBio, Inc.

Approval Confirmed

ANKTIVA

non-muscle invasive bladder cancer (NMIBC) carcinoma in situ (CIS)

Resolved

187days ago

Approval decision · Jan 1, 2026

What's at stake A final FDA approval decision on ANKTIVA for non-muscle invasive bladder cancer (NMIBC) carcinoma in situ (CIS) is expected Jan 1, 2026.

Primary source · SEC 8-K verified 14h ago

“Kingdom of Saudi Arabia : SFDA accelerated approval, January 2026 (NMIBC CIS with or without papillary tumors; metastatic non-small cell lung cancer)”

Add to calendar Post on X Reddit

Provenance